Your browser doesn't support javascript.
loading
International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
Heidsma, Charlotte M; van Roessel, Stijn; van Dieren, Susan; Engelsman, Anton F; Strobel, Oliver; Buechler, Markus W; Schimmack, Simon; Perinel, Julie; Adham, Mustapha; Deshpande, Vikram; Kjaer, Josefine; Norlen, Olov; Gill, Anthony J; Samra, Jaswinder S; Mittal, Anubhav; Hoogwater, Frederik J H; Primavesi, Florian; Stättner, Stefan; Besselink, Marc G; van Eijck, Casper H J; Nieveen van Dijkum, E J M.
Afiliação
  • Heidsma CM; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • van Roessel S; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • van Dieren S; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Engelsman AF; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Strobel O; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
  • Buechler MW; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
  • Schimmack S; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
  • Perinel J; Department of Surgery, Centre Hospitalier Universitaire de Lyon, University of Lyon, Lyon, France.
  • Adham M; Department of Surgery, Centre Hospitalier Universitaire de Lyon, University of Lyon, Lyon, France.
  • Deshpande V; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Kjaer J; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Norlen O; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Gill AJ; Cancer Diagnosis and Pathology Group Kolling Institute of Medical Research and University of Sydney, Sydney, New South Wales, Australia.
  • Samra JS; Department of Surgery, Royal North Shore Hospital, St Leonards, University of Sydney, Sydney, New South Wales, Australia.
  • Mittal A; Department of Surgery, Royal North Shore Hospital, St Leonards, University of Sydney, Sydney, New South Wales, Australia.
  • Hoogwater FJH; Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Primavesi F; Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.
  • Stättner S; Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.
  • Besselink MG; Department of Surgery, Salzkammergut Klinikum, Standort Vocklabruck, Vocklabruck, Austria.
  • van Eijck CHJ; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Nieveen van Dijkum EJM; Department of Surgery, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Neuroendocrinology ; 112(6): 571-579, 2022.
Article em En | MEDLINE | ID: mdl-34343138
ABSTRACT

BACKGROUND:

Despite the low recurrence rate of resected nonfunctional pancreatic neuroendocrine tumors (NF-pNETs), nearly all patients undergo long-term surveillance. A prediction model for recurrence may help select patients for less intensive surveillance or identify patients for adjuvant therapy. The objective of this study was to assess the external validity of a recently published model predicting recurrence within 5 years after surgery for NF-pNET in an international cohort. This prediction model includes tumor grade, lymph node status and perineural invasion as predictors.

METHODS:

Retrospectively, data were collected from 7 international referral centers on patients who underwent resection for a grade 1-2 NF-pNET between 1992 and 2018. Model performance was evaluated by calibration statistics, Harrel's C-statistic, and area under the curve (AUC) of the receiver operating characteristic curve for 5-year recurrence-free survival (RFS). A sub-analysis was performed in pNETs >2 cm. The model was improved to stratify patients into 3 risk groups (low, medium, high) for recurrence.

RESULTS:

Overall, 342 patients were included in the validation cohort with a 5-year RFS of 83% (95% confidence interval [CI] 78-88%). Fifty-eight patients (17%) developed a recurrence. Calibration showed an intercept of 0 and a slope of 0.74. The C-statistic was 0.77 (95% CI 0.70-0.83), and the AUC for the prediction of 5-year RFS was 0.74. The prediction model had a better performance in tumors >2 cm (C-statistic 0.80).

CONCLUSIONS:

External validity of this prediction model for recurrence after curative surgery for grade 1-2 NF-pNET showed accurate overall performance using 3 easily accessible parameters. This model is available via www.pancreascalculator.com.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Tumores Neuroendócrinos / Tumores Neuroectodérmicos Primitivos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Tumores Neuroendócrinos / Tumores Neuroectodérmicos Primitivos Idioma: En Ano de publicação: 2022 Tipo de documento: Article